A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of SC411 in Children With Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Docosahexaenoic acid (Primary) ; Soya oil emulsion
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms SCOT
- Sponsors Sancilio & Company
- 03 Apr 2018 According to a Sancilio Pharmaceuticals media release, detailed data from this study will be published in peer reviewed journals and will be presented in upcoming scientific conferences.
- 01 Nov 2017 Primary endpoint has been met. (Change from baseline in the blood cells omega-3 fatty acids index),according to Sancilio Pharmaceuticals media release.
- 01 Nov 2017 Topline results published in a Sancilio Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History